The World Health Organization announced on Tuesday that international scientific research consortiums have successfully identified six promising direct-acting antiviral drug candidates for treating dengue fever, with one lead molecule advancing into phase-three clinical efficacy trials.
Addressing a global health assembly in Geneva, WHO infectious disease specialists emphasized that developing targeted therapeutics is urgent as warming climate conditions accelerate the geographic footprint of Aedes mosquito vectors across Latin America, Southeast Asia, and southern Europe. Historically, medical care for dengue infections has been restricted to supportive hydration therapies, blood platelet monitoring, and fever management.
The lead antiviral candidate, developed through multilateral partnerships involving academic research hubs and pharmaceutical innovators, functions by inhibiting the non-structural viral protease required for dengue replication inside human host cells. Early clinical trial data demonstrated significant reductions in viral load and a sharp decline in life-threatening complications, including dengue hemorrhagic fever and severe plasma leakage.
Global health authorities stated that multinational clinical trials are currently enrolling thousands of adult and pediatric patients across endemic regions in India, Brazil, and Indonesia. The WHO affirmed its commitment to establishing global access treaties to guarantee affordable antiviral procurement for vulnerable populations upon regulatory authorization.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://theprint.in/india/maharashtra-five-cyber-fraudsters-arrested-by-ulhasnagar-police/3037477/